Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding.
Zhe YuLing GaoYinshan ZangLu ChengWenjia GaoYan XuPublished in: Immunity, inflammation and disease (2024)
ADA shows superiority over ETN in terms of a numerically greater response rate and equivalent adverse events.